As­traZeneca taps two more tar­gets from its AI part­ner, again in CKD and IPF

As­traZeneca is dou­bling down in chron­ic kid­ney dis­ease and id­io­path­ic pul­monary fi­bro­sis by se­lect­ing one tar­get for each of those via its AI-pow­ered part­ner.

Orig­i­nal­ly teamed up in 2019, the Big Phar­ma has now se­lect­ed a to­tal of five tar­gets via its UK coun­ter­part, Benev­o­len­tAI. The tal­ly in­cludes two tar­gets in CKD and three in IPF, a lung-scar­ring and breath­ing-con­stric­tion dis­ease with two ap­proved drugs — Boehringer In­gel­heim’s Ofev and Roche’s Es­bri­et, both giv­en the nod in 2014 — and a re­cent gener­ic en­try.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER